Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma

被引：11
|
作者：
da Silva, Priscilla Brito [1 ]
Real, Juliana Monte [2 ,3 ,4 ]
Pinto Ferreira, Ludmila Rodrigues [5 ]
Esteves, Gustavo H. [6 ]
Brito, Fabio do Nascimento [1 ]
Baiocchi, Otavio C. G. [1 ,7 ]
机构：
[1] Univ Fed Sao Paulo, UNIFESP, Dept Oncol Clin & Expt, Sao Paulo, Brazil
[2] Inst Canc Estado Sao Paulo, Ctr Invest Translac Oncol, Sao Paulo, Brazil
[3] Hosp Serv Publ Estadual Sao Paulo, IAMSPE, Sao Paulo, Brazil
[4] Hosp Santa Marcelina, Assoc TUCCA Criancas & Adolescentes Com Canc, Dept Oncol Pediat, Sao Paulo, Brazil
[5] Univ Fed Minas Gerais, ICB UFGM, Inst Ciencias Biol, Dept Morphol, Belo Horizonte, MG, Brazil
[6] Univ Estadual Paraiba, UEPB, Dept Estat, Campina Grande, Brazil
[7] HAOC, Hematol Div, Sao Paulo, Brazil
来源：
HEMATOLOGICAL ONCOLOGY | 2018年 / 36卷 / 04期
基金：
巴西圣保罗研究基金会;
关键词：
DEATH-LIGAND; 1; MICROENVIRONMENT; EXPRESSION;
D O I：
10.1002/hon.2542
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：709 / 712
页数：4
相关论文
共 50 条
  • [21] PD-1/PD-L1 inhibitors
    Sunshine, Joel
    Taube, Janis M.
    CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
  • [22] Drug response to PD-1/PD-L1 blockade: based on biomarkers
    Chen, Qi
    Li, Tianhe
    Yue, Wentao
    ONCOTARGETS AND THERAPY, 2018, 11 : 4673 - 4683
  • [23] The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
    Xueping Wang
    Fang Wang
    Mengjun Zhong
    Yosef Yarden
    Liwu Fu
    Molecular Cancer, 19
  • [24] PD-1/PD-L1 in disease
    Kuol, Nyanbol
    Stojanovska, Lily
    Nurgali, Kulmira
    Apostolopoulos, Vasso
    IMMUNOTHERAPY, 2018, 10 (02) : 149 - 161
  • [25] Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
    Zhu, Xinxin
    Lang, Jinghe
    ONCOTARGET, 2017, 8 (57) : 97671 - 97682
  • [26] The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
    Wang, Xueping
    Wang, Fang
    Zhong, Mengjun
    Yarden, Yosef
    Fu, Liwu
    MOLECULAR CANCER, 2020, 19 (01)
  • [27] Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
    Meng, Xiangjiao
    Huang, Zhaoqin
    Teng, Feifei
    Xing, Ligang
    Yu, Jinming
    CANCER TREATMENT REVIEWS, 2015, 41 (10) : 868 - 876
  • [28] Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1
    Darabi, Sourat
    Braxton, David R.
    Eisenberg, Burton L.
    Demeure, Michael J.
    ONCOLOGY-NEW YORK, 2020, 34 (08): : 321 - 327
  • [29] Immunohistochemical assessment of the PD-1/PD-L1 axis in follicular lymphoma
    Szumera-Cieckiewicz, A.
    Sokol, K.
    Rymkiewicz, G.
    Jastrzebska, A.
    Paszkiewicz-Kozik, E.
    Kotarska, M.
    Walewski, J.
    Prochorec-Sobieszek, M.
    VIRCHOWS ARCHIV, 2018, 473 : S97 - S98
  • [30] IFN-γ upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1/PD-L1 blockade
    Pistillo, Maria Pia
    Carosio, Roberta
    Banelli, Barbara
    Morabito, Anna
    Mastracci, Luca
    Ferro, Paola
    Varesano, Serena
    Vene, Roberta
    Poggi, Alessandro
    Roncella, Silvio
    CELLULAR & MOLECULAR IMMUNOLOGY, 2020, 17 (04) : 410 - 411
12345